Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Virtuix expands Omni One VR system sales to Europe
03:41am, Wednesday, 11'th Feb 2026
Virtuix Holdings Inc (NASDAQ:VTIX), a developer of full-body virtual reality systems, said on Wednesday it has expanded sales of its Omni One platform to...
Arizona Gold & Silver appoints Darin Wagner as CEO advisor
03:35am, Wednesday, 11'th Feb 2026
Arizona Gold & Silver Inc (TSX-V:AZS, OTCQB:AZASF, FRA:A9J0) announced that it has appointed Darin Wagner as an advisor to the company’s chief executive...
Novo Nordisk: How Low Is Too Low? (Downgrade, Technical Analysis)
03:17pm, Tuesday, 10'th Feb 2026
Novo Nordisk A/S has seen its stock fall sharply, driven by a dramatic slowdown in EPS growth and weak 2026 guidance. A large drop was justified. This article looks at whether it could be overdone. Te
Why Cheaper GLP-1 Drugs Are Facing Legal Battles
01:01pm, Tuesday, 10'th Feb 2026
The push to make weight loss drugs more affordable is running into legal limits. Telehealth company Hims & Hers pulled a less expensive oral version of Wegovy after lawsuits from Novo Nordisk and risi
Novo Nordisk: Ugly Guidance, But Stock Refuses To Break Down Further
10:33am, Tuesday, 10'th Feb 2026
Keeping my Buy rating on Novo Nordisk A/S despite a disappointing negative 2026 sales guidance amid fierce competition from Eli Lilly and compounders. NVO's Wegovy pill launch shows encouraging early
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
10:00am, Tuesday, 10'th Feb 2026
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Novo Nordisk Rallies 3.6% as Hims & Hers Pulls Compounded Semaglutide
08:16am, Tuesday, 10'th Feb 2026
NVO shares jump 3.6% after Hims & Hers halts compounded semaglutide following an FDA warning and patent lawsuit.
First Look: Novo sues Hims, BP halts buybacks, Meta faces trial
07:39am, Tuesday, 10'th Feb 2026
Stock News Novo sues Hims over compounded weight-loss drugs: Novo Nordisk (NVO) filed suit to stop Hims and Hers Health (HIMS) from selling compounded semaglutide
Novo Nordisk opens new front with patent suit over Hims' Wegovy copies
06:04am, Tuesday, 10'th Feb 2026
Novo Nordisk's U.S. patent lawsuit against Hims & Hers , filed on Monday, marks a new front in the Danish pharmaceutical drugmaker's campaign against companies selling compounded versions of its block
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
04:17am, Tuesday, 10'th Feb 2026
Bagsværd, Denmark, 10 February 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated
Novo Nordisk: Full Kitchen Sink Reset Or Another Shoe Yet To Drop?
05:55pm, Monday, 09'th Feb 2026
Novo Nordisk A/S shares plunged ~25% after sharply lowered 2026 revenue and profit guidance, driven by unexpectedly steep US price declines and competitive pressures. Hims's $49‑per‑month oral Weg
Market Today: Novo sues Hims; Highlander EV; Alphabet bond
05:36pm, Monday, 09'th Feb 2026
Guru Stock PicksChuck Royce has made the following transactions:Reduce in NATL by 11.01%Sold out in DENNAdd in SXC by 106.69%New position in AZZKen Fisher has m
FDA Flags Novo Wegovy Pill Ad; Shares Par Gains After 8.95% Rise
04:05pm, Monday, 09'th Feb 2026
Novo Nordisk A/S (NVO) is facing fresh regulatory friction after the US Food and Drug Administration said a television advertisement for its new weight-loss pil
Novo Nordisk, Hims & Hers Health Shares React to Lawsuit
03:44pm, Monday, 09'th Feb 2026
Pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) revealed today it is pursing legal action against Hims & Hers Health Inc (NYSE:HIMS) for alleged patent infringement, after the telehealth giant in
Novo Nordisk vs. Eli Lilly: What's the Better Long-Term Investment?
02:30pm, Monday, 09'th Feb 2026
Eli Lilly has been a growth beast and its top line may soar by as much as 27% this year. Novo Nordisk is bracing for a potential double-digit decline in sales, as it tries to fight off copycat version
